Kala Bio stock plunges after failed Phase 2b trial for eye treatment
NegativeFinancial Markets

Kala Bio's stock has taken a significant hit following the disappointing results of its Phase 2b trial for an eye treatment. This setback is crucial as it raises concerns about the company's future prospects and the viability of its product pipeline, impacting investor confidence and potentially delaying advancements in eye care.
— Curated by the World Pulse Now AI Editorial System